This site is intended for US residents only.

• HTML Foundation Styles

 

HTML tagsFont NameFont SizeLine Height
<h1></h1>

Montserrat

61px73px
<h2></h2>

Montserrat

49px59px
<h3></h3>

Montserrat

39px47px
<h4></h4>

Montserrat

31px37px
<h5></h5>
Montserrat
25px30px
<h6></h6>
Montserrat
20px24px
<p></p>

IBM Plex Sans

16px26px
<b></b>

Montserrat

16px19px

 

 

• Strong Font Styles

ℹ️ It was tested in headings and paragraphs.

 

HTML tagsStrong Font StylesFont NameFont SizeLine Height
<h1-h6>Step 5Montserrat61px73px
<p>Step 5IBM Plex Sans61px98px
<p><b>Step 5Montserrat61px73px
<h1-h6>Step 4Montserrat49px59px
<p>Step 4IBM Plex Sans49px78px
<p><b>Step 4Montserrat49px59px
<h1-h6>Step 3Montserrat39px47px
<p>Step 3IBM Plex Sans39px62px
<p><b>Step 3Montserrat39px47px
<h1-h6>Step 2Montserrat31px37px
<p>Step 2IBM Plex Sans31px50px
<p><b>Step 2Montserrat31px47px
<h1-h6>Step 1Montserrat25px30px
<p>Step 1IBM Plex Sans25px40px
<p><b>Step 1Montserrat25px30px
<h1-h6>Step 0Montserrat20px24px
<p>Step 0IBM Plex Sans20px32px
<p><b>Step 0Montserrat20px24px
<h1-h6>Step -1Montserrat16px19px
<p>Step -1IBM Plex Sans16px26px
<p><b>Step -1Montserrat16px19px
<h1-h6>Step -2Montserrat13px15px
<p>Step -2IBM Plex Sans13px20px
<p><b>Step -2Montserrat13px15px
<h1-h6>Step -3Montserrat10px12px
<p>Step -3IBM Plex Sans10px16px
<p><b>Step -3Montserrat10px12px

💡 Examples:

 

h1-h6: Step 5

p: Step 5

p + b : Step 5

h1-h6: Step 4

p: Step 4
p + b : Step 4

h1-h6: Step 3

p: Step 3

p + b : Step 3

h1-h6: Step 2

p: Step 2

p + b : Step 2

h1-h6: Step 1

p: Step 1

p + b : Step 1

h1-h6: Step 0

p: Step 0

p + b : Step 0

h1-h6: Step -1

p: Step -1

p + b : Step -1

h1-h6: Step -2

p: Step -2

p + b : Step -2

h1-h6: Step -3

p: Step -3

p + b : Step -3

• Text Font Styles

⚠️ It only applies to paragraphs; it doesn’t work in headings.

 

HTML tagsText Font StylesFont NameFont SizeLine Height
<p>Step 2IBM Plex Sans31px50px
<p>Step 1IBM Plex Sans25px40px
<p>Step 0IBM Plex Sans20px32px
<p>Step -1IBM Plex Sans16px26px
<p>Step -2IBM Plex Sans13px20px
<p>Step -3IBM Plex Sans10px16px
- - - - - - - - - - - -
HTML tagsText Font StylesFont NameFont SizeLine Height
<p><b>Step 2IBM Plex Sans31px50px
<p><b>Step 1IBM Plex Sans25px40px
<p><b>Step 0IBM Plex Sans20px32px
<p><b>Step -1IBM Plex Sans16px26px
<p><b>Step -2IBM Plex Sans13px20px
<p><b>Step -3IBM Plex Sans10px16px

💡 Examples:

 

p: Step 2

p: Step 2

p: Step 0

p: Step -1

p: Step -2

p: Step -3

 

 

 

 

 

 

💡 Examples b:

 

p: Step 2

p: Step 2

p: Step 0

p: Step -1

p: Step -2

p: Step -3

• Bold Pattern

ℹ️ It was tested in headings and paragraphs.

 

HTML tagsBold PatternFont NameFont SizeLine Height
h1LightMontserrat61px73px
h2LightMontserrat49px59px
h3LightMontserrat39px47px
h4LightMontserrat31px37px
h5LightMontserrat25px30px
h6LightMontserrat20px24px
pLightIBM Plex Sans16px26px
 
h1Light ItalicMontserrat61px73px
h2Light ItalicMontserrat49px59px
h3Light ItalicMontserrat31px37px
h4Light ItalicMontserrat25px30px
h5Light ItalicMontserrat20px24px
h6Light ItalicMontserrat16px26px
pLight ItalicIBM Plex Sans16px26px
 
h1RegularMontserrat61px73px
h2RegularMontserrat49px59px
h3RegularMontserrat31px37px
h4RegularMontserrat25px30px
h5RegularMontserrat20px24px
h6RegularMontserrat16px26px
pRegularIBM Plex Sans16px26px
 
h1ItalicMontserrat61px73px
h2ItalicMontserrat49px59px
h3ItalicMontserrat31px37px
h4ItalicMontserrat25px30px
h5ItalicMontserrat20px24px
h6ItalicMontserrat16px26px
pItalicIBM Plex Sans16px26px
 
h1Semi BoldMontserrat61px73px
h2Semi BoldMontserrat49px59px
h3Semi BoldMontserrat39px47px
h4Semi BoldMontserrat31px37px
h5Semi BoldMontserrat25px30px
h6Semi BoldMontserrat20px24px
pSemi BoldIBM Plex Sans16px26px
 
h1Semi Bold ItalicMontserrat61px73px
h2Semi Bold ItalicMontserrat49px59px
h3Semi Bold ItalicMontserrat39px47px
h4Semi Bold ItalicMontserrat31px37px
h5Semi Bold ItalicMontserrat25px30px
h6Semi Bold ItalicMontserrat20px24px
pSemi Bold ItalicIBM Plex Sans16px26px
 
h1BoldMontserrat61px73px
h2BoldMontserrat49px59px
h3BoldMontserrat39px47px
h4BoldMontserrat31px37px
h5BoldMontserrat25px30px
h6BoldMontserrat20px24px
pBoldIBM Plex Sans16px26px
Bold Italic
h1Bold ItalicMontserrat61px73px
h2Bold ItalicMontserrat49px59px
h3Bold ItalicMontserrat39px47px
h4Bold ItalicMontserrat31px37px
h5Bold ItalicMontserrat25px30px
h6Bold ItalicMontserrat20px24px
pBold ItalicIBM Plex Sans16px26px

💡 Examples:

 

h1: Light

h2: Light

h3: Light

h4: Light

h5: Light
h6: Light

p: Light

h1: Light Italic

h2: Light Italic

h3: Light Italic

h4: Light Italic

h5: Light Italic
h6: Light Italic

p: Light Italic

h1: Regular

h2: Regular

h3: Regular

h4: Regular

h5: Regular
h6: Regular

p: Regular

h1: Italic

h2: Italic

h3: Italic

h4: Italic

h5: Italic
h6: Italic

p: Italic

h1: Semi Bold

h2: Semi Bold

h3: Semi Bold

h4: Semi Bold

h5: Semi Bold
h6: Semi Bold

p: Semi Bold

h1: Semi Bold Italic

h2: Semi Bold Italic

h3: Semi Bold Italic

h4: Semi Bold Italic

h5: Semi Bold Italic
h6: Semi Bold Italic

p: Semi Bold Italic

h1: Bold 

h2: Bold 

h3: Bold 

h4: Bold 

h5: Bold 
h6: Bold 

p: Bold 

h1: Bold Italic

h2: Bold Italic

h3: Bold Italic

h4: Bold Italic

h5: Bold Italic
h6: Bold Italic

p: Bold Italic

What is VYLOY?

IMPORTANT SAFETY INFORMATION

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

  • cannot be removed with surgery or has spread to other parts of the body,
  • is HER2-negative, and
  • your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

  • have nausea or vomiting.
  • are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

  • Allergic reactions, including anaphylaxis and infusion-related reactions. Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions and serious infusion-related reactions that may lead to death. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
  • itchy, raised bumps on the skin (hives)
  • coughing that does not go away
  • nausea or vomiting
  • stomach (abdominal) pain
  • increased saliva
  • breathing problems such as wheezing
  • throat tightness or change in voice
  • fever
  • chest discomfort
  • chills or shaking
  • back pain
  • Severe nausea and vomiting. Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

  • tiredness
  • decreased appetite
  • diarrhea
  • tingling or numbness of the arms or legs
  • stomach (abdominal) pain
  • constipation
  • decreased weight
  • fever
  • decreased white blood cells, red blood cells and platelets
  • decreased protein (albumin) in the blood
  • changes in kidney function tests
  • changes in blood sugar (glucose)
  • changes in liver function tests
  • changes in body salts (electrolytes) in your blood

Your healthcare provider may slow the rate of your infusion, temporarily stop, or completely stop treatment with VYLOY if you have certain side effects. These are not all of the possible side effects of VYLOY. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Patient Information.

What is VYLOY?

IMPORTANT SAFETY INFORMATION

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

  • cannot be removed with surgery or has spread to other parts of the body,
  • is HER2-negative, and
  • your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

  • have nausea or vomiting.
  • are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

  • Allergic reactions, including anaphylaxis and infusion-related reactions. Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions and serious infusion-related reactions that may lead to death. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
  • itchy, raised bumps on the skin (hives)
  • coughing that does not go away
  • nausea or vomiting
  • stomach (abdominal) pain
  • increased saliva
  • breathing problems such as wheezing
  • throat tightness or change in voice
  • fever
  • chest discomfort
  • chills or shaking
  • back pain
  • Severe nausea and vomiting. Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

  • tiredness
  • decreased appetite
  • diarrhea
  • tingling or numbness of the arms or legs
  • stomach (abdominal) pain
  • constipation
  • decreased weight
  • fever
  • decreased white blood cells, red blood cells and platelets
  • decreased protein (albumin) in the blood
  • changes in kidney function tests
  • changes in blood sugar (glucose)
  • changes in liver function tests
  • changes in body salts (electrolytes) in your blood

Your healthcare provider may slow the rate of your infusion, temporarily stop, or completely stop treatment with VYLOY if you have certain side effects. These are not all of the possible side effects of VYLOY. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Patient Information.